Tysabri and Progressive Multifocal Leukoencephalopathy: Recognizing the Signs

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Risk Communication to Specific Prognostic Inquiry

If you or a loved one is taking Tysabri and experiencing new neurological symptoms like confusion or vision changes, you may be worried about progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection requires prompt medical attention. Historically, understanding medication risks has been central to informed treatment decisions, and this page provides a clear overview of PML, its connection to Tysabri, and what current research says about outcomes.

Tysabri and PML: A Direct Causal Link

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The prognosis for patients who develop PML from Tysabri is poor, with the condition often leading to permanent disability or death. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug 'increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning underscores the permanent nature of the harm, as PML typically results in irreversible neurological damage. The infection destroys the myelin sheaths that protect nerve cells, leading to progressive deficits in motor function, vision, speech, and cognition. While some patients may survive, the majority experience lasting impairments that significantly reduce quality of life.

Clinical Evidence of Permanence

The permanence of PML from Tysabri is supported by clinical data. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 multiple sclerosis patients treated for a median of 120 weeks, and both patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1,043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases illustrate that PML can develop even with relatively short exposure, and the outcomes are consistently severe. The mechanism linking Tysabri to PML involves the drug's effect on immune surveillance. Tysabri blocks the alpha-4 integrin receptor on immune cells, preventing them from crossing the blood-brain barrier. This reduces inflammation in the central nervous system, which is beneficial for treating multiple sclerosis, but it also impairs the brain's ability to fight the JC virus. The JC virus is normally kept in check by a healthy immune system, but when immune cells cannot enter the brain, the virus can reactivate and cause PML. This mechanistic pathway explains why Tysabri increases PML risk and why the damage is often permanent: once the virus destroys brain tissue, the body cannot regenerate it.

Risk Factors and Monitoring

Risk factors for developing PML from Tysabri include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment. The FDA requires that Tysabri be prescribed only through the TOUCH Prescribing Program, a restricted distribution program designed to monitor patients for PML symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these precautions, PML can still occur, and the prognosis remains grim. The timeline between Tysabri exposure and PML diagnosis varies. In clinical trials, one patient developed PML after eight doses, while others developed it after longer treatment periods. Importantly, PML has been reported after discontinuation of Tysabri in patients who did not have symptoms at the time of stopping the drug. The FDA advises that patients should be monitored for new signs or symptoms suggestive of PML for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This delayed onset complicates prognosis, as the infection may progress before it is detected.

Prognosis and Long-Term Outcomes

For patients who develop PML, the prognosis is poor. The FDA boxed warning states that PML 'usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Survivors often have permanent neurological deficits, such as paralysis, vision loss, or cognitive impairment. The severity of these deficits depends on the extent of brain damage at the time of diagnosis. Early detection and treatment, such as plasma exchange to remove Tysabri from the bloodstream, may improve outcomes, but they do not reverse existing damage. The permanence of PML from Tysabri is a critical consideration for patients and healthcare providers. In summary, PML from Tysabri is a permanent condition that typically results in death or severe disability. The risk is increased by anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. The FDA has issued strong warnings and requires monitoring through the TOUCH program, but the prognosis for affected patients remains poor. The timeline between exposure and harm can be variable, and PML can occur even after treatment is stopped. These factors highlight the importance of careful risk-benefit analysis when using Tysabri.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Is PML from Tysabri permanent?

Yes, PML from Tysabri is typically permanent. The infection destroys myelin sheaths in the brain, leading to irreversible neurological damage. The FDA boxed warning states that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Survivors often have lasting deficits such as paralysis, vision loss, or cognitive impairment.

What are the risk factors for developing PML from Tysabri?

Risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be assessed before and during treatment.

Can PML occur after stopping Tysabri?

Yes, PML has been reported after discontinuation of Tysabri in patients who did not have symptoms at the time of stopping. The FDA recommends monitoring for new signs of PML for at least six months after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA Boxed Warning for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.